COS Funding Opportunities Search

COS Funding Opportunities™

COS Unique Id:	100610
Title:	Vision Grant
Sponsor:	Society of Critical Care Medicine (SCCM)
Sponsor Type:	Professional Society or Association
Deadline:	September 4, 2008
Upper Amount:	$50,000
Amount Note:	The maximum level of funding is $50,000 per year. Grant recipients will be announced at the Society of Critical Care Medicine's Convocation and Award Ceremony at the Critical Care Congress.
Eligibility:	The principal investigator must be a current SCCM member and maintain SCCM membership through the life of the grant. Applications are encouraged from both established and junior investigators from all critical care disciplines. Applications from junior investigators (defined as Assistant Professor or below) may be a request for independent support or may include a research mentor who is also an SCCM member and who demonstrates strong research credentials in the areas of clinical and outcomes research. To be eligible for the Vision Grant, the applicant may not apply for five years if they were a previous winner.
Citizenship or Residency:	Unrestricted
Activity Location:	Unrestricted
Requirements:	Ph.D./M.D./Other Professional
Abstract:	SCCM, in collaboration with the Critical Care Education and Research Foundation (CCERF), announces the availability for grant support for SCCM members focused on clinical and outcomes research specifically related to the Society's four goals and objectives: 1. Education (Learn It) 2. Integrated Team of Dedicated Experts (Deliver It) 3. Outcomes Measurements and Reporting (Measure It) 4. Continuous Improvement (Improve It) SCCM seeks to sponsor research efforts that will ultimately improve patient care in the intensive care unit (ICU). Investigator-initiated research should help expand and advance the understanding of clinical outcomes specifically related to these goals. SCCM's interest is broad. For example, the society encourages applications that focus on technical aspects, such as electronic surveillance systems, yet similarly encourage studies exploring cultural and educational factors among ICU staff that either impede or facilitate a climate promoting best practice and error reduction. SCCM will give priority to projects that have broad relevance. As one extension of this, single center projects, for example, should specifically address the potential to generalize their findings to other critical care settings. Grant recipients will also be required to submit an abstract for blind review for presentation at SCCM Annual Congress.
Contact Name:	Trish Glover
Contact Address:	Society of Critical Care Medicine 500 Midway Drive
Contact City:	Mount Prospect
Contact State:	Illinois
Contact Zip:	60056
Contact Country:	United States
Contact Phone:	+1 (847) 493-6440
Contact Email:	pglover@sccm.org
URL for more information:	http://www.sccm.org/Membership/Grants/Pages/VisionGrant.aspx
Date Last Revised:	April 24, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=100610
Keywords:	Critical Care Patient Care and Education Patient Care Management
Funding Type:	Research

COS Unique Id:	105169
Title:	Major Grants
Sponsor:	PepsiCo Foundation
Sponsor Type:	Private Foundation
Deadline:	September 15, 2008
Amount Note:	Requests over $100,000 are accepted.
Eligibility:	Applicant organizations must be tax-exempt as defined under section 501 (c)(3) of the Internal Revenue Code. While the Foundation generally prefers to invest in local U.S. communities where PepsiCo has a presence, it also funds international programs. Typically, PepsiCo Foundation chooses to work with academic and community organizations where there are established relationships.
Citizenship or Residency:	Unrestricted
Activity Location:	Unrestricted
Requirements:	Nonprofit Academic Institution
Abstract:	PepsiCo Foundation is the primary charitable arm of PepsiCo, Inc. and has a long history of and commitment to corporate citizenship, demonstrating PepsiCo's core value of caring for the communities in which its employees live and work. The PepsiCo Foundation focuses its grant making in the following areas: 1. The Foundation's mission in Health and Wellness is to advance the knowledge about how to encourage healthy lifestyles and effect positive behavior change. Initiatives of particular interest are those which address one or more of the following focus areas: a. Community Activation b.Minority Communities c.Health Professionals 2. PepsiCo Foundation's mission in Diversity and Inclusion is to support education and community organizations which advance opportunities in three core areas: 1.Undergraduate and graduate education, skill development and economic mobility 2. Women- and minority-owned business 3. Workplace equality Specifically, the Foundation provides support to a select number of colleges and universities which provide opportunities for individuals of all backgrounds to gain leadership skills and experience. Programs at the high school level with an emphasis on skill development for students of color and students from low-income households also receive Foundation support. The Foundation also considers organizations which help foster a positive environment for minority-owned and women-owned businesses as well as workplace climate for gay, lesbian, bisexual and transgender communities. 3. The Foundation's mission around the Environment is to advance the knowledge and methods of water resource management which are sustainable and positively impact both quantity and quality of water supply in developing nations. 4. Under the Thought Leadership initiative, the Foundation supports organizations and research initiatives which help to address issues critical to the betterment of society.
Contact Name:	Director, Corporate Contributions
Contact Address:	PepsiCo, Inc. 700 Anderson Hill Road
Contact City:	Purchase
Contact State:	New York
Contact Zip:	10577
Contact Country:	United States
Contact Phone:	+1 (914) 253-2000
URL for more information:	http://www.pepsico.com/PEP_Citizenship/Contributions/GrantGuidelines/index.cfm
Date Last Revised:	April 24, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=105169
Keywords:	Behavior Modification Community Development or Revitalization Community or Outreach Programs Community Services Cultural Diversity Environmental Sciences Health and Medicine Health Behavior Health Promotion Minority Health Natural Resources Management Water Quality Water Supply
Funding Type:	Program or Curriculum Development or Provision

COS Unique Id:	112751
Title:	Methods for Prevention Packages Program (MP3) (R01)
Sponsor:	Department of Health and Human Services (HHS) National Institutes of Health (NIH)
Sponsor Type:	Federal, U.S.
Deadline:	August 25, 2008
Deadline Note:	An optional letter of intent is due July 25, 2008. This opportunity expires August 26, 2008. Renewal and resubmission applications are not permitted in response to this FOA.
Upper Amount:	$2,400,000
Amount Note:	This FOA will utilize the NIH Research Project Grant (R01) award mechanism. The NIAID intends to award up to $4 million in FY 2009 to fund four to six applications submitted in response to this FOA. NIMH is also providing $500,000 in support of this FOA. Applicants may request a project period of up to four years and a budget of up to $600,000 in direct costs in each year, plus applicable facilities and administrative costs. This program does not require cost sharing.
Eligibility:	Applications may be submitted by domestic or foreign, for-profit or nonprofit organizations and public or private institutions, such as universities, colleges, hospitals, and laboratories; units of state and local governments; eligible agencies of the federal government; and faith-based or community-based organizations.
Citizenship or Residency:	Unrestricted
Activity Location:	Unrestricted
Requirements:	Small Business Ph.D./M.D./Other Professional Commercial Government Nonprofit Academic Institution
Abstract:	The National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Mental Health (NIMH) invite applications for multidisciplinary research programs that - devise optimal HIV prevention packages (combination interventions) for specific populations; - design clinical studies to rigorously examine the safety and efficacy of these "packages" in the target population; and - perform pilot studies to demonstrate that the proposed prevention package is acceptable to the target population and the study design is appropriate and feasible. This FOA is intended to encourage collaborations between behavioral and biomedical clinical scientists, epidemiologists, mathematical modelers, and clinical trial design specialists. It is expected that teams conducting this research will perform a systematic review and meta-analysis of existing prevention research data germane to the target population(s) chosen. These data can be used to develop a mathematical model to assess the impact of various combinations of interventions which have been shown to reduce HIV incidence in the same or similar settings. If mathematical modeling is performed, sensitivity analyses showing how the outcome is influenced by key risk behaviors and other variables should be provided. The impact of incomplete adherence, risk compensation, and other behavioral factors should also be considered. A full discussion of the key assumptions of the mathematical model should be provided. Sensitivity analyses showing how the outcome is influenced by key risk behaviors and other variables (e.g., stage of the epidemic, dominant modes of transmission in the population, proportion of persons in major risk groups, etc., as appropriate) should be provided. The impact of incomplete adherence, risk compensation, and other behavioral factors should also be considered. A full discussion of the key assumptions of the mathematical model should be provided. The prevention packages should include both biomedical and behavioral interventions that can be applied in a complementary manner in the target population. As indicated, interventions to optimize adherence and minimize disinhibition (risk compensation) should be included. The population selected may be a specific high-risk group, such as African American men who have sex with men (MSM) or injection drug users in Eastern Europe; a nation as a whole, such as the population of Thailand, with its specific combination of risk groups, risk behaviors, and incidence rates; or a region, such as southern Africa. Selection of populations that are most affected by the epidemic in a given setting (e.g., women and youth in South Africa) is strongly encouraged. The team should carefully examine the strengths and limitations of the research design chosen to evaluate the proposed prevention package(s), making comparisons with alternative designs. The control intervention should include HIV risk reduction counseling, free condoms, and other behavioral and biomedical interventions considered standard of care. Finally, the team should (a) perform a pilot study to demonstrate that the proposed prevention package is acceptable to the target population, and (b) present convincing evidence that the research design proposed is feasible operationally and will provide a conclusive assessment of the prevention package's safety and efficacy. The latter should include evidence that sufficient HIV incidence events will occur in the proposed setting, sample population, and follow-up period. A phase 1 clinical study may be adequate to demonstrate that the prevention package is acceptable to the target population. Applicants are encouraged to discuss the scope of the pilot study with NIAID program staff prior to submission.
Contact Name:	Lisa Scott-Morring, M.S.
Contact Address:	Division of Extramural Activities Room 2232, MSC-7614 6700B Rockledge Drive
Contact City:	Bethesda
Contact State:	Maryland
Contact Zip:	20892-7614
Contact Country:	United States
Contact Phone:	+1 (301) 451-3697
Contact Fax:	+1 (301) 493-0597
Contact Email:	ScottLi@niaid.nih.gov
URL for more information:	http://grants1.nih.gov/grants/guide/rfa-files/RFA-AI-08-044.html
Date Last Revised:	April 24, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=112751
Keywords:	HIV Prevention
Sponsor Reference No:	RFA-AI-08-044
Funding Type:	Collaboration or Cooperative Agreement Research

COS Unique Id:	113584
Title:	PHASE II Comprehensive ICOHRTA AIDS/TB (U2R)
Sponsor:	Department of Health and Human Services (HHS) National Institutes of Health (NIH)
Sponsor Type:	Federal, U.S.
Deadline:	August 18, 2008 August 18, 2009
Deadline Note:	Non-required letters of intent are due July 19, 2008, and July 18, 2009. This opportunity will expire on August 19, 2009. Internal coordination required. Only one application for a Phase II Comprehensive ICOHRTA AIDS TB award will be allowed from any foreign institution in response to this FOA. In situations in which more than one planning grant has been awarded to institutions in close proximity in the same country, applicants will be strongly encouraged to submit a single, integrated application for a Phase II award. Only one Phase II award will be made to any foreign institution in the ICOHRTA AIDS TB program.
Amount Note:	This FOA will utilize the International Training Cooperative Agreement (U2R) grant mechanism. The estimated amount of funds available for support of five to six new or renewal Research Training Units awarded as a result of this announcement is $3,000,000 for fiscal year 2009. Future year amounts will depend on annual appropriations. Facilities and administrative costs are limited to 8 percent for all awards and sub-awards. Each new Phase II ICOHRTA AIDS TB applicant in a Research Training Unit may request a project period of up to five years and a budget for direct costs up to $275,000 dollars for the first year. The Phase II Comprehensive ICOHRTA-AIDS/TB applicants that comprise the Research Training Unit may request up to $550,000 in combined direct costs for each year. In the first budget year, the foreign institution's direct cost budget must be at a direct cost level equal to or greater than its linked partner institution's. The foreign institution's direct cost budget may increase in years two through five to reflect the increased capacity of the foreign applicant to facilitate training and research. The foreign institution's direct cost budget may exceed $275,000 in years two through five, but the combined direct costs each year for the Research Training Unit (two linked awards) may not exceed $550,000. Applicants in a renewal Phase II ICOHRTA AIDS TB Research Training Unit may each submit an application requesting a project period of up to five years and a combined budget of up to $550,000 in direct costs for each year. The direct cost budget for the foreign institution applicant in the Research Training Unit should be at least 60 percent of the combined budget. Alternatively, the foreign institution in the renewal Research Training Unit may submit one application for the Research Training Unit in which the U.S. partner(s) are funded through a sub-award. In this situation, the budget submitted on the application may not exceed $550,000 in direct costs for each year and the combined sub-awards to any U.S. institutions should not exceed 40 percent of the requested budget. This program does not require cost sharing.
Eligibility:	Eligible applicants include institutions of higher education, nonprofits, and non-domestic organizations. New applications for a Phase II Comprehensive ICOHRTA-AIDS/TB Award will only be accepted from foreign institutions that were awarded a planning grant under a Phase I ICOHRTA-AIDS/TB program competition and the U.S. nonprofit partner institution that the planning grant recipient has chosen. The foreign and U.S. partner applicant institutions must have achieved a strong record of receiving or being significantly involved in HIV/AIDS and/or TB international research. Both the foreign and U.S. partner institutions must demonstrate the capacity and leadership necessary for the successful implementation and long-term productivity of the program. Renewal applications will only be accepted from existing ICOHRTA AIDS TB recipients. The PD in a new Phase II application from the foreign institution is expected to be the PD from the Phase I award. Any changes in PD in renewal applications of a Research Training Unit need to be well-justified. Both the foreign and U.S. partner PDs must be directly involved in and funded to do research in resource-poor settings and there must be tangible evidence of very strong linkage to that ongoing research as collaborating partners. The PDs must hold faculty or other long-term research positions at a public or private nonprofit research institution that will allow them adequate time and provide appropriate facilities, salary support and resources, including access to patients or patient data, when necessary. To a limited extent and with prior FIC approval, U.S. trainees will be eligible for foreign research experience under this cooperative agreement. To be eligible, they must have uniquely relevant expertise and skills that will contribute to the training, research, or administration at the foreign institution and have a major career commitment to international research.
Citizenship or Residency:	Unrestricted
Activity Location:	Unrestricted
Requirements:	Ph.D./M.D./Other Professional Nonprofit Academic Institution
Abstract:	This FOA, issued by the Fogarty International Center (FIC), National Institute of Mental Health (NIMH), Office of Research on Women's Health (ORWH), and National institute on Drug Abuse (NIDA), solicits renewal (re-competing) and new Phase II applications in the International Clinical, Operations and Health Services Research Training Award for AIDS and TB (ICOHRTA AIDS TB) program. The applications from a Research Training Unit, composed of a Phase I ICOHRTA AIDS TB (planning grant) recipient and the U.S. partner institution chosen by the Phase I recipient, must propose, in an integrated manner, a comprehensive training program that will strengthen the capacity in the foreign country to conduct clinical research and implementation science, including operations and health services research focused on HIV infection, TB, and, where relevant, HIV/TB co-infection prevention, care and treatment. The objectives of the ICOHRTA AIDS TB program are to - develop research training programs for integrated clinical research and implementation science at foreign institutions in low or middle-income countries (LMICs) where HIV and/or TB are significant problems (Over time, these institutions will become national, regional and international centers of excellence in implementation science for HIV and /or TB.); - develop a cadre of "implementation science" experts that can address issues of importance for HIV and TB prevention, care and treatment in their country and region; - support training-related research (degree-related or mentored research projects) that address issues of importance to implementation of HIV and/or TB interventions and are directly relevant to the needs of the people in the foreign country, are appropriate to local circumstances and most likely to affect public health policy; - rapidly strengthen the research training capacity and infrastructure required for success by building on existing programs involved with the implementation of prevention, care and treatment interventions for HIV and/or TB in the country; and - strengthen core research support capabilities needed to manage research grants at the foreign institution. Each Phase II Comprehensive ICOHRTA-AIDS/TB program application should incorporate an appropriate mix of long-, intermediate- and short-term training opportunities in a wide range of relevant disciplines and skills necessary to advance implementation science. The proposed training should strengthen sustainable clinical research and implementation science, including operations and health services research, and core research support capacity at the foreign site. Training can take place at the U.S. or foreign sites, but training-related research should be carried out mainly in the country of the foreign institution. While a range of short-, intermediate- and long-term training is allowable, emphasis will be on intermediate- to longer-term training, including mid-career training and advanced in-country research.
Contact Name:	Ms. Elizabeth Cleveland, Grants Management Officer
Contact Address:	Fogarty International Center National Institutes of Health Building 31, Room B2C29
Contact City:	Bethesda
Contact State:	Maryland
Contact Zip:	20892-2220
Contact Country:	United States
Contact Phone:	+1 (301) 451-6830
Contact Fax:	+1 (301) 594-1211
Contact Email:	clevelande@mail.nih.gov
URL for more information:	http://grants1.nih.gov/grants/guide/pa-files/PAR-08-155.html
Date Last Revised:	April 22, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=113584
Keywords:	Health or Nutrition Programs - Developing Countries HIV Infectious Diseases or Agents Tuberculosis
Sponsor Reference No:	PAR-08-155
Funding Type:	Collaboration or Cooperative Agreement Program or Curriculum Development or Provision

COS Unique Id:	113587
Title:	Biomarkers of Infection-Associated Cancers (R01)
Sponsor:	Department of Health and Human Services (HHS) National Institutes of Health (NIH)
Sponsor Type:	Federal, U.S.
Deadline:	June 5, 2008 October 5, 2008 February 5, 2009
Deadline Note:	The opening date is May 5, 2008. This opportunity will expire on May 8, 2011.
Amount Note:	This FOA uses the NIH research project R01 grant mechanism. The total project period for an application submitted in response to this funding opportunity may not exceed five years. Applicants for an R01 award are not limited in dollars but need to reflect the actual needs of the proposed project. This program does not require cost sharing.
Eligibility:	Eligible applicants include institutions of higher education; nonprofits, for-profits, and small businesses; state and local governments; eligible agencies of the federal government; and non-domestic organizations.
Citizenship or Residency:	Unrestricted
Activity Location:	Unrestricted
Requirements:	Small Business Ph.D./M.D./Other Professional Commercial Government Nonprofit Academic Institution
Abstract:	This FOA, issued by the National Cancer Institute (NCI) and the National Institute of Dental and Craniofacial Research (NIDCR), encourages applications from institutions and organizations that propose to identify biomarkers for cancers where the etiology of the disease is attributed to infectious agents. This initiative encourages research to identify molecular markers for risk assessment and early detection in individuals exposed to infectious agents that have been linked to cancer. Listed below, but not limited to, are several programmatic areas in need of support for developing molecular signatures for infectious agent-associated cancers: 1. Molecular profiles of normal, precancerous, and cancerous lesions following infection and of body fluids from infected individuals: Infectious agents interact with host cells and activate sets of infectious agent-specific and host-specific genes and proteins. Often some of these proteins are secreted into extracellular fluids. Samples utilized for studies may be derived from tissues or body fluids (e.g., serum, nipple aspirate, pancreatic juice, sputum, urine, alveolar lavage, saliva). It is advantageous if marker profiles can be obtained from body fluids that are collected using minimally invasive methodologies. In addition, chronic inflammation in response to the infectious agent may play a role in cancer development. It may be possible that indicators of inflammation or immune activation could also be useful indices of cancer predisposition. 2. Evaluation of these molecular profiles for use in gaining a better understanding of the role of infectious agents in cancer development and use in early detection, risk assessment, and prevention of cancer: In all known cases, infectious agents that are associated with cancers persist for long periods in the host before cancer develops. How the host responds to the infectious agents and how the agent modulates this response are critical in allowing for its persistence and may determine the risk of cancer. Molecular profiles should be analyzed to determine whether a single biomarker, panel of biomarkers, or molecular patterns can be used to determine which infected individuals are at risk of developing cancer and to determine the transition from chronic infection to the initiation of cancer. These molecular profiles may also be used to identify targets for cancer prevention and therapeutic vaccine development. Research projects proposed in the applications may involve a number of infectious agents showing associations with cancer. Noteworthy viral agents of interest to this program are human papillomavirus (HPV), Hepatitis B and C viruses, Epstein-Barr virus (EBV), and Simian Virus 40. Furthermore, an escalating prevalence of early cervical, lung, and colon cancers has emerged among HIV patients. Applicants are also invited to investigate bacterial etiology in cancer, such as the role of Helicobacter pylori in the development of gastric cancers. The involvement of parasitic infections in various cancers is also relevant to this FOA. The NIDCR has particular interest in EBV- and HPV-associated head and neck cancers. Research projects covering basic science (infectious life cycle, viral replication, etc.) or treatment studies of these infectious agents without direct relevance to cancer biomarker development are not encouraged by this FOA. Using the NIH Research Project Grant (R01) funding mechanism, this FOA focuses on discrete, specified, circumscribed projects based upon strong preliminary data.
Contact Name:	Jane Paull
Contact Address:	Office of Grants Administration National Cancer Institute 6120 Executive Boulevard, EPS Room 243, MSC 7150
Contact City:	Bethesda
Contact State:	Maryland
Contact Zip:	20892-7150
Contact Country:	United States
Contact Phone:	+1 (301) 496-2182
Contact Fax:	+1 (301) 496-8601
Contact Email:	paullj@mail.nih.gov
URL for more information:	http://grants1.nih.gov/grants/guide/pa-files/PA-08-156.html
Date Last Revised:	April 22, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=113587
Keywords:	Biomarkers Cancer Biology
Sponsor Reference No:	PA-08-156
Funding Type:	Research

COS Unique Id:	113588
Title:	Biomarkers of Infection-Associated Cancers (R21)
Sponsor:	Department of Health and Human Services (HHS) National Institutes of Health (NIH)
Sponsor Type:	Federal, U.S.
Deadline:	June 16, 2008 October 16, 2008 February 16, 2009
Deadline Note:	The opening date is May 16, 2008. This opportunity will expire on May 8, 2011.
Upper Amount:	$275,000
Amount Note:	This FOA utilizes the NIH Exploratory/Developmental Grant (R21) mechanism. The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year. The R21 is not renewable. This program does not require cost sharing.
Eligibility:	Eligible applicants include institutions of higher education; nonprofits, for-profits, and small businesses; state and local governments; eligible agencies of the federal government; and non-domestic organizations.
Citizenship or Residency:	Unrestricted
Activity Location:	Unrestricted
Requirements:	Small Business Ph.D./M.D./Other Professional Commercial Government Nonprofit Academic Institution
Abstract:	This FOA, issued by the National Cancer Institute (NCI) and the National Institute of Dental and Craniofacial Research (NIDCR), encourages applications from institutions and organizations that propose to identify biomarkers for cancers where the etiology of the disease is attributed to infectious agents. This initiative encourages research to identify molecular markers for risk assessment and early detection in individuals exposed to infectious agents that have been linked to cancer. Listed below, but not limited to, are several programmatic areas in need of support for developing molecular signatures for infectious agent-associated cancers: 1. Molecular profiles of normal, precancerous, and cancerous lesions following infection and of body fluids from infected individuals: Infectious agents interact with host cells and activate sets of infectious agent-specific and host-specific genes and proteins. Often some of these proteins are secreted into extracellular fluids. Samples utilized for studies may be derived from tissues or body fluids (e.g., serum, nipple aspirate, pancreatic juice, sputum, urine, alveolar lavage, saliva). It is advantageous if marker profiles can be obtained from body fluids that are collected using minimally invasive methodologies. In addition, chronic inflammation in response to the infectious agent may play a role in cancer development. It may be possible that indicators of inflammation or immune activation could also be useful indices of cancer predisposition. 2. Evaluation of these molecular profiles for use in gaining a better understanding of the role of infectious agents in cancer development and use in early detection, risk assessment, and prevention of cancer: In all known cases, infectious agents that are associated with cancers persist for long periods in the host before cancer develops. How the host responds to the infectious agents and how the agent modulates this response are critical in allowing for its persistence and may determine the risk of cancer. Molecular profiles should be analyzed to determine whether a single biomarker, panel of biomarkers, or molecular patterns can be used to determine which infected individuals are at risk of developing cancer and to determine the transition from chronic infection to the initiation of cancer. These molecular profiles may also be used to identify targets for cancer prevention and therapeutic vaccine development. Research projects proposed in the applications may involve a number of infectious agents showing associations with cancer. Noteworthy viral agents of interest to this program are human papillomavirus (HPV), Hepatitis B and C viruses, Epstein-Barr virus (EBV), and Simian Virus 40. Furthermore, an escalating prevalence of early cervical, lung, and colon cancers has emerged among HIV patients. Applicants are also invited to investigate bacterial etiology in cancer, such as the role of Helicobacter pylori in the development of gastric cancers. The involvement of parasitic infections in various cancers is also relevant to this FOA. The NIDCR has particular interest in EBV- and HPV-associated head and neck cancers. Research projects covering basic science (infectious life cycle, viral replication, etc.) or treatment studies of these infectious agents without direct relevance to cancer biomarker development are not encouraged by this FOA. Using the NIH Exploratory Grant (R21) funding mechanism, this FOA focuses on early and conceptual stages of research projects.
Contact Name:	Jane Paull
Contact Address:	Office of Grants Administration National Cancer Institute 6120 Executive Boulevard, EPS Room 243, MSC 7150
Contact City:	Bethesda
Contact State:	Maryland
Contact Zip:	20892-7150
Contact Country:	United States
Contact Phone:	+1 (301) 496-2182
Contact Fax:	+1 (301) 496-8601
Contact Email:	paullj@mail.nih.gov
URL for more information:	http://grants1.nih.gov/grants/guide/pa-files/PA-08-157.html
Date Last Revised:	April 22, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=113588
Keywords:	Biomarkers Cancer Biology
Sponsor Reference No:	PA-08-157
Funding Type:	Research

COS Unique Id:	3063
Title:	Potts Memorial Foundation Grant
Sponsor:	Potts Memorial Foundation
Sponsor Type:	Private Foundation
Deadline Note:	Continuous. The trustees of the foundation meet the first Friday in May and the third Friday in October to consider grants. Proposals should reach the office at least 30 days prior to each meeting date.
Eligibility:	Charitable organizations are eligible to apply.
Citizenship or Residency:	Unrestricted
Activity Location:	Unrestricted
Requirements:	Nonprofit
Abstract:	The foundation provides funds for the care, treatment, and rehabilitation of persons afflicted with tuberculosis. Support may include maintenance operations of hospitals; research; vocational counseling and guidance; grants to hospitals and charitable institutions; and the operation of sheltered workshops.
Contact Name:	Charles E. Inman, Secretary
Contact Address:	Potts Memorial Foundation P.O. Box 1015
Contact City:	Hudson
Contact State:	New York
Contact Zip:	12534
Contact Country:	United States
Contact Phone:	+1 (518) 828-3365
Date Last Revised:	April 21, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=3063
Keywords:	Patient Care and Education Rehabilitation or Therapy Tuberculosis
Funding Type:	Research Facility Construction or Operation Program or Curriculum Development or Provision

COS Unique Id:	32505
Title:	Conservation and the Environment
Sponsor:	Mellon Foundation, Andrew W.
Sponsor Type:	Private Foundation
Deadline Note:	Continuous. Unsolicited proposals are rarely funded. Prospective applicants are therefore encouraged not to submit a full proposal initially, but a short query letter that sets forth the need, nature, and amount of their request, along with evidence of suitable classification by the Internal Revenue Service.
Amount Note:	Junior Faculty Research Grants have ranged up to approximately $300,000.
Citizenship or Residency:	Unrestricted
Activity Location:	Unrestricted
Requirements:	Ph.D./M.D./Other Professional Nonprofit
Abstract:	The Foundation's program in Conservation and the Environment (C&E) has evolved from interests originally stated by the Avalon and Old Dominion Foundations as including the preservation of natural areas and the support of "organizations concerned with increasing man's understanding of his natural environment, his relation to it, and the effects of his activities upon it." The activities described below are the only areas within which the Foundation is currently accepting inquiries: 1. Junior Faculty Research grants are awarded to new faculty as they begin their first tenure-track positions. The awards do not replace start-up research funds provided by colleges or universities and are only made after those arrangements are in place. The idea is to provide intellectual venture capital to promising researchers at the critical and formative stage when they begin their independent research careers. This program is devoted to basic research on how natural ecosystems work. It emphasizes support of leading institutions, innovative research, and the training of promising doctoral and postdoctoral researchers. The Foundation limits its activities to the United States and joint projects with institutions in South Africa that are linked to its other activities there. 2. The C&E portion of the AWMF South Africa program is centered on creating research bridges between the U.S. universities and South African universities, the South African National Parks System and the South African National Biodiversity Institution. The Foundation has worked to strengthen the capacity of these two institutions to work effectively with university scientists and students - and provided support to engage university research groups from both South Africa and the USA in collaborative research with them. The general aims and guidelines for this portion of the program are the same as those described for Junior Faculty research grants above. New grants are restricted to proposals that link directly to the extant program. 3. The African and Latin American Plants Initiatives are partnerships of 85 herbaria from 31 countries working to create a database of high quality images of plant type specimens of African and Latin American plants. The grants are limited to institutions holding African and Latin American plant type specimens. The resulting database is available to scholars at www.aluka.org and through www.JSTOR.org. The Foundation will be glad to hear from any institutions holding African and/or Latin American plant type specimens that it has not yet reached.
Contact Name:	William Robertson IV, Program Officer
Contact Address:	Andrew W. Mellon Foundation 140 East 62nd Street
Contact City:	New York
Contact State:	New York
Contact Zip:	10065
Contact Country:	United States
Contact Phone:	+1 (212) 500-2497
Contact Fax:	+1 (212) 500-2302
Contact Email:	wr@mellon.org
URL for more information:	http://www.mellon.org/grant_programs/programs/conservation
Date Last Revised:	April 25, 2008
URL from COS to Bookmark this record:	http://fundingopps.cos.com/cgi-bin/getRec?id=32505
Keywords:	Botany Ecosystems Environmental Conservation Environmental Law Environmental Sciences Land Management or Land Use Terrestrial Ecology
Funding Type:	Research Program or Curriculum Development or Provision